Editas Medicine Inc (EDIT)
2.37
-0.04
(-1.66%)
USD |
NASDAQ |
Nov 21, 16:00
2.39
+0.02
(+0.84%)
Pre-Market: 09:24
Editas Medicine Enterprise Value: -69.45M for Nov. 21, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 21, 2024 | -69.45M |
| November 20, 2024 | -66.15M |
| November 19, 2024 | -60.37M |
| November 18, 2024 | -57.07M |
| November 15, 2024 | -45.51M |
| November 14, 2024 | -36.43M |
| November 13, 2024 | -20.75M |
| November 12, 2024 | -11.67M |
| November 11, 2024 | 7.321M |
| November 08, 2024 | -7.538M |
| November 07, 2024 | -3.410M |
| November 06, 2024 | 5.670M |
| November 05, 2024 | -7.538M |
| November 04, 2024 | -27.35M |
| November 01, 2024 | -24.87M |
| October 31, 2024 | -25.70M |
| October 30, 2024 | -15.79M |
| October 29, 2024 | -8.393M |
| October 28, 2024 | 3.988M |
| October 25, 2024 | -2.615M |
| October 24, 2024 | -2.615M |
| October 23, 2024 | -0.1391M |
| October 22, 2024 | 6.464M |
| October 21, 2024 | 45.26M |
| October 18, 2024 | 12.24M |
| Date | Value |
|---|---|
| October 17, 2024 | 8.115M |
| October 16, 2024 | 19.67M |
| October 15, 2024 | 12.24M |
| October 14, 2024 | 2.337M |
| October 11, 2024 | -1.790M |
| October 10, 2024 | -20.77M |
| October 09, 2024 | -7.568M |
| October 08, 2024 | -3.441M |
| October 07, 2024 | -0.1391M |
| October 04, 2024 | 13.89M |
| October 03, 2024 | -0.9645M |
| October 02, 2024 | 0.6863M |
| October 01, 2024 | 4.813M |
| September 30, 2024 | 16.37M |
| September 27, 2024 | 7.906M |
| September 26, 2024 | 8.731M |
| September 25, 2024 | 0.483M |
| September 24, 2024 | 12.03M |
| September 23, 2024 | 22.75M |
| September 20, 2024 | 31.82M |
| September 19, 2024 | 43.37M |
| September 18, 2024 | 40.90M |
| September 17, 2024 | 39.25M |
| September 16, 2024 | 36.77M |
| September 13, 2024 | 46.67M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-69.45M
Minimum
Nov 21 2024
5.265B
Maximum
Jan 08 2021
1.000B
Average
582.07M
Median
Feb 14 2022
Enterprise Value Benchmarks
| Ionis Pharmaceuticals Inc | 4.154B |
| EyePoint Pharmaceuticals Inc | 316.10M |
| Cassava Sciences Inc | 1.399B |
| Adverum Biotechnologies Inc | -33.63M |
| Regenxbio Inc | 199.36M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -62.14M |
| Revenue (Quarterly) | 0.061M |
| Total Expenses (Quarterly) | 65.73M |
| EPS Diluted (Quarterly) | -0.75 |
| Profit Margin (Quarterly) | -101.9K% |
| Earnings Yield | -108.0% |
| Normalized Earnings Yield | -108.02 |